aliqopa-us.comAliqopa™(copanlisib) | Official Patient Site
aliqopa-us.com Profile
aliqopa-us.com
Sub Domains:hcp.aliqopa-us.com
Title:Aliqopa™(copanlisib) | Official Patient Site
Description:Visit the official website for Aliqopa™ (copanlisib). Aliqopa is not a chemotherapy. Learn about patient support to help you on your treatment journey.
Discover aliqopa-us.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
aliqopa-us.com Information
Website / Domain: |
aliqopa-us.com |
HomePage size: | 33.36 KB |
Page Load Time: | 0.465664 Seconds |
Website IP Address: |
149.234.240.121 |
Isp Server: |
Bayer Business Services GmbH |
aliqopa-us.com Ip Information
Ip Country: |
Germany |
City Name: |
Leverkusen |
Latitude: |
51.030300140381 |
Longitude: |
6.9843201637268 |
aliqopa-us.com Keywords accounting
aliqopa-us.com Httpheader
Server: Apache |
HCVer: 115 |
Content-Type: text/html; charset=UTF-8 |
Vary: Accept-Encoding |
Content-Encoding: gzip |
HAVer: 113 |
Content-Length: 7985 |
Cache-Control: max-age=30029362 |
Expires: Tue, 28 Dec 2021 03:31:32 GMT |
Date: Thu, 14 Jan 2021 14:02:10 GMT |
Connection: keep-alive |
aliqopa-us.com Meta Info
charset="utf-8"/ |
content="IE=edge" http-equiv="X-UA-Compatible"/ |
content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport" |
content="Visit the official website for Aliqopa™ (copanlisib). Aliqopa is not a chemotherapy. Learn about patient support to help you on your treatment journey." name="description"/ |
content="" name="author"/ |
content="telephone=no" name="format-detection"/ |
149.234.240.121 Domains
aliqopa-us.com Similar Website
Domain |
WebSite Title |
aliqopa-us.com | Aliqopa™(copanlisib) | Official Patient Site |
try.2020onsite.com | Patient FAQ and Contact Us - 2020 On-site |
cologuardtest.com | At-Home Colon Cancer Screening | Cologuard® Patient Site | Risk Info |
members.pmai.us | Patient Directory - Find Local Patients - Trusted Patient Reviews |
ambien.com | AMBIEN® and AMBIEN® CR | Official Patient Site |
manuals.spacelabshealthcare.com | Spacelabs Healthcare - Patient Monitoring & Patient Health CareSpacelabs Healthcare |
relatient.net | Patient Engagement Solutions | Patient Engagement Platform - Relatient |
medicationguide.ambien.com | AMBIEN® and AMBIEN® CR Official Patient Site |
11016-1.portal.athenahealth.com | Patient Portal |
id.patientfusion.com | Patient Fusion |
my.njhealth.org | Patient Portal |
8209-2.portal.athenahealth.com | Patient Portal |
myrecords.goshenhealth.com | Patient Portal |
5872.portal.athenahealth.com | Patient Portal |
ehealth.bahc.com | Patient Portal |
aliqopa-us.com Traffic Sources Chart
aliqopa-us.com Alexa Rank History Chart
aliqopa-us.com Html To Plain Text
Full Prescribing Information Important Safety Information For Healthcare Professionals A A A -- IMPORTANT SAFETY INFORMATION Infections: ALIQOPA can cause serious infections that may lead to death. The most common serious infection was pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA. Continue reading below Demonstrated Results Financial Access Sign Up -- Aliqopa ™ is a treatment for relapsed * follicular lymphoma (FL) and it is not chemotherapy Aliqopa is a prescription medicine used to treat adults with FL when the disease has come back after treatment with at least two prior medicines. It is not known if Aliqopa is safe and effective in children. Aliqopa was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment. There is an ongoing study to confirm the benefit of Aliqopa for this use. Not actual patients. * Relapsed FL means that FL has recurred or the signs and symptoms have come back after a period of improvement. Demonstrated Results See the study results for Aliqopa. View Results Financial Access Get information about insurance coverage and financial assistance for Aliqopa. Go to Financial Access Free Nutritional Support Learn more about complimentary and individually customized nutritional resources. Sign Up -- What is ALIQOPA? ALIQOPA is a prescription medicine used to treat adults with follicular lymphoma (FL) when the disease has come back after treatment with at least two prior medicines. It is not known if ALIQOPA is safe and effective in children. ALIQOPA was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment. There is an ongoing study to confirm the benefit of ALIQOPA for this use. Important Safety Information ALIQOPA can cause serious side effects, including: Infections: ALIQOPA can cause serious infections that may lead to death. The most common serious infection was pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA. ALIQOPA can cause serious side effects, including: -- High blood sugar (hyperglycemia): High blood sugar is common following ALIQOPA infusion and can sometimes be serious. Tell your healthcare provider if you develop any symptoms of hyperglycemia during treatment with ALIQOPA. Symptoms of hyperglycemia may include being very hungry, being very thirsty, frequent urination and headaches. High blood pressure (hypertension): High blood pressure is common following ALIQOPA infusion and can sometimes be serious. Lung or breathing problems: Your healthcare provider may do tests to check your lungs if you have breathing problems during treatment with ALIQOPA. Tell your healthcare provider right away if you develop new or worsening cough, shortness of breath, or difficulty breathing. Low white blood cell count (neutropenia): Neutropenia is common with ALIQOPA treatment and can sometimes be serious. Your healthcare provider will check your blood counts regularly during treatment with ALIQOPA. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with ALIQOPA. Severe skin reactions: Skin peeling, rash, and itching are common with ALIQOPA and can sometimes be serious. Tell your healthcare provider if you develop skin peeling, itching, or rash during treatment with ALIQOPA. Your healthcare provider may withhold treatment, decrease your dose, or permanently stop treatment if you develop severe skin reactions during treatment with ALIQOPA. Before receiving ALIQOPA, tell your healthcare provider about all of your medical conditions, including if you: have an infection have lung or breathing problems have high blood pressure (hypertension) have diabetes or high blood sugar (hyperglycemia) are pregnant or plan to become pregnant. ALIQOPA can harm your unborn baby. Your healthcare provider will perform a pregnancy test before starting treatment with ALIQOPA. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with ALIQOPA. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA. are breastfeeding or plan to breastfeed. It is not known if ALIQOPA passes into your breast milk. Do not breastfeed during treatment with ALIQOPA and for at least 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about the best way to feed your child during treatment with ALIQOPA. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ALIQOPA works. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. What should I avoid while receiving ALIQOPA? Avoid taking St. John’s Wort during treatment with ALIQOPA. Avoid drinking grapefruit juice during treatment with ALIQOPA. The most common side effects of ALIQOPA include: low white blood cell count (leukopenia) low platelets in your blood (thrombocytopenia) diarrhea decreased strength and tiredness lower respiratory tract infection nausea These are not all of the possible side effects of ALIQOPA. Call your doctor for medical advice about side effects. For important risk and use information about Aliqopa, please see the full Prescribing Information . You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here . FPO -- © 2019 Bayer. All rights reserved. Bayer, the Bayer Cross, Aliqopa, and ARC are registered trademarks of Bayer. This site is intended for US audiences only. Site last modified: 11/2019 Terms and Conditions Privacy Policy Contact Us California Transparency in Supply Chains ATTENTION You are now leaving the Aliqopa TM (copanlisib) website. Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements. Thank you for visiting Aliqopa. Continue Cancel ATTENTION You are now leaving the Aliqopa TM (copanlisib) website. Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements. Thank you for visiting Aliqopa. Continue Cancel ATTENTION You are now leaving the Aliqopa TM (copanlisib) website. Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements. Thank you for visiting Aliqopa. Cancel -- Continue ATTENTION You are now leaving the Aliqopa TM (copanlisib) website. Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements. Thank you for visiting Aliqopa. Cancel -- Continue Fill out the fields below to share a link to this page All fields required Name: From: To: Subject: [ Name ] thought this website might be of interest to you Message: I thought you might be interested in this information about Aliqopa ™ (copanlisib) Click here to learn more. Submit Cancel Thank you. Your request has been sent. Download and Print the Patient Brochure For information and tips for when you rece...
aliqopa-us.com Whois
"domain_name": [
"ALIQOPA-US.COM",
"aliqopa-us.com"
],
"registrar": "CSC CORPORATE DOMAINS, INC.",
"whois_server": "whois.corporatedomains.com",
"referral_url": null,
"updated_date": [
"2019-07-02 05:35:07",
"2020-10-21 12:03:14"
],
"creation_date": [
"2017-07-06 15:24:01",
"2017-07-06T11:24:01.000-04:00"
],
"expiration_date": [
"2021-07-06 15:24:01",
"2021-07-06T11:24:01.000-04:00"
],
"name_servers": [
"PDNS1.CSCDNS.NET",
"PDNS2.CSCDNS.NET",
"pdns1.cscdns.net",
"pdns2.cscdns.net"
],
"status": [
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited"
],
"emails": [
"domainabuse@cscglobal.com",
"domainnames@bayer.com",
"dns-admin@cscglobal.com"
],
"dnssec": "unsigned",
"name": "Domain Administrator",
"org": "Bayer AG",
"address": "Kaiser-Wilhelm-Allee 1",
"city": "Leverkusen",
"state": "North Rhine-Westphalia",
"zipcode": "51368",
"country": "DE"